Filing Details
- Accession Number:
- 0001567619-21-018628
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-22 21:42:32
- Reporting Period:
- 2021-10-20
- Accepted Time:
- 2021-10-22 21:42:32
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1650648 | 4D Molecular Therapeutics Inc. | FDMT | Biological Products, (No Disgnostic Substances) (2836) | 473506994 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1692929 | David Schaffer | C/O 4D Molecular Therapeutics Inc. 5858 Horton Street #455 Emeryville CA 94608 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-10-20 | 11,565 | $31.02 | 925,935 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-10-21 | 22,820 | $31.56 | 903,115 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-10-22 | 1,900 | $31.00 | 901,215 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- The transaction was executed in multiple trades in prices ranging from $30.27 to $32.07,inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $30.70 to $32.39, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $30.76 to $31.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.